Brian King, Director of the FDA's Center for Tobacco Products, is set to participate in a public dialogue next month regarding e-cigarettes and harm reduction. King took on the role of Director in July 2022 and began implementing strong regulations on e-cigarettes, including strengthening the review process for PMTA, and issuing warning letters to non-compliant companies. Prior to this dialogue, King only made an appearance and delivered a speech at the Global Tobacco and Nicotine Forum in September of last year and has not interacted with the public since. This dialogue will be his first public interaction with industry professionals since taking on the role.
Brian King's speech at GTNF | Source: 2FIRSTS
The upcoming online event will be hosted by Gregory Conley, the Director of Legislation for the American Vaping Association (AVM), and newly appointed Vice President of AVM, Allison Boughner. The conference, titled "The Future of American Vaping: A Conversation with Dr. Brian King, Director of the FDA Center for Tobacco Products," will take place on February 24th at 1:00 pm EST and is open to the public, with registration available through this link.
According to 2FIRSTS, it is understood that the director King's speech at this conference may reveal the future direction of electronic cigarette regulation by the United States federal government.
The Washington News Center editor will provide extensive coverage of the event and bring updates as they become available. Stay tuned for more information.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
